P3 Health Partners (NASDAQ:PIII) Trading Up 3% - Still a Buy?

Key Points

• P3 Health Partners' share price increased by 3%, reaching a last trading price of $8.91 with 7,700 shares traded, indicating a decline of 13% from its average session volume.
• Analyst ratings for P3 Health Partners are mixed, with one analyst rating it as a Buy, one as a Hold, and one as a Sell, resulting in an average rating of "Hold" and a consensus target price of $16.25.
• The company reported a significant loss per share of ($6.23), missing predictions by $2.94 and showing a gross revenue of $355.79 million in its most recent earnings report.

P3 Health Partners Inc. (NASDAQ:PIII - Get Free Report)'s share price shot up 3% on Monday . The company traded as high as $9.08 and last traded at $8.91. 7,700 shares were traded during trading, a decline of 13% from the average session volume of 8,897 shares. The stock had previously closed at $8.65.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on PIII shares. Lake Street Capital assumed coverage on P3 Health Partners in a research report on Thursday, August 28th. They set a "buy" rating and a $20.00 price objective on the stock. Weiss Ratings restated a "sell (e+)" rating on shares of P3 Health Partners in a report on Saturday, September 27th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, P3 Health Partners currently has an average rating of "Hold" and a consensus target price of $16.25.

P3 Health Partners Stock Performance

The firm has a market cap of $64.06 million, a P/E ratio of -0.19 and a beta of 0.84. The company has a debt-to-equity ratio of 2.29, a quick ratio of 0.31 and a current ratio of 0.31. The business's 50-day simple moving average is $8.00 and its 200 day simple moving average is $7.77.

P3 Health Partners (NASDAQ:PIII - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($6.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.29) by ($2.94). The firm had revenue of $355.79 million during the quarter, compared to analysts' expectations of $356.52 million. P3 Health Partners had a negative return on equity of 183.60% and a negative net margin of 9.99%. P3 Health Partners has set its FY 2025 guidance at EPS. As a group, equities analysts predict that P3 Health Partners Inc. will post -0.67 earnings per share for the current year.

Institutional Trading of P3 Health Partners

Large investors have recently added to or reduced their stakes in the business. Trinity Financial Advisors LLC increased its holdings in P3 Health Partners by 22.5% during the first quarter. Trinity Financial Advisors LLC now owns 1,278,037 shares of the company's stock valued at $222,000 after buying an additional 234,500 shares during the last quarter. Abundance Wealth Counselors grew its position in shares of P3 Health Partners by 77.3% during the 1st quarter. Abundance Wealth Counselors now owns 400,000 shares of the company's stock valued at $66,000 after acquiring an additional 174,395 shares during the period. Finally, Cresset Asset Management LLC increased its stake in shares of P3 Health Partners by 33.3% in the 1st quarter. Cresset Asset Management LLC now owns 200,000 shares of the company's stock worth $33,000 after purchasing an additional 50,000 shares in the last quarter. 7.75% of the stock is currently owned by institutional investors.

About P3 Health Partners

P3 Health Partners Inc, a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc was founded in 2020 and is based in Henderson, Nevada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.